Market Place
Sourcing Support
Neurona Therapeutics Announces Participation In October Conferences
27 Sep 2024 //
GLOBENEWSWIRE
Neurona Gets $3.8M CIRM Grant For Neural Cell Therapy
10 Sep 2024 //
GLOBENEWSWIRE
Neurona Appoints Dr. Nadia as Senior Vice President of Regulatory Affairs
26 Jun 2024 //
GLOBENEWSWIRE
Neurona Receives FDA’s Regenerative Medicine Advance Therapy (RMAT) Designation
18 Jun 2024 //
GLOBENEWSWIRE
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
11 Jun 2024 //
GLOBENEWSWIRE
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference
28 May 2024 //
GLOBENEWSWIRE
Neurona: NRTX-1001 Epilepsy Data At AAN 2024
15 Apr 2024 //
GLOBENEWSWIRE
Neurona Therapeutics to Present at Stifel 2024 Virtual CNS Days
12 Mar 2024 //
GLOBENEWSWIRE
Neurona Therapeutics Announces Presentation of Updated Clinical Data
07 Mar 2024 //
GLOBENEWSWIRE
Neurona raises $120M to take epilepsy cell therapy to late-stage development
08 Feb 2024 //
ENDPTS
Neurona knocks out $120M raise a year after layoffs
08 Feb 2024 //
FIERCE BIOTECH
Neurona Therapeutics to Present at the Oppenheimer 34th Annual Conference
07 Feb 2024 //
GLOBENEWSWIRE
Neurona Therapeutics Presents Data from Phase I/II Open-Label Trial of NRTX-1001
01 Dec 2023 //
GLOBENEWSWIRE
Neurona Therapeutics Completes Enrollment in Phase I/II Trial of NRTX-1001
19 Oct 2023 //
GLOBENEWSWIRE
Neurona Announces Participation in Upcoming Investor Conferences in October
10 Oct 2023 //
GLOBENEWSWIRE
Neurona Therapeutics Announces Publication in Cell Stem Cell
05 Oct 2023 //
GLOBENEWSWIRE
Neurona Appoints James Stutz as Chief Financial Officer & Chief Business Officer
31 Jul 2023 //
GLOBENEWSWIRE
Neurona Presents One-Year Data on the First Patient Treated with NRTX-1001
15 Jun 2023 //
GLOBENEWSWIRE
Neurona’s brain stem cell therapy shows early efficacy in epilepsy
15 Jun 2023 //
CLINICAL TRIALS ARENA
Neurona Therapeutics Presents Updated Data from the NRTX-1001
24 Apr 2023 //
GLOBENEWSWIRE
Neurona Announce FDA Clearance of Expanded Criteria for PI/II Trial of NRTX-1001
14 Feb 2023 //
GLOBENEWSWIRE
Epilepsy and Alzheimer`s cell therapy biotech lays off 25% of staff
07 Feb 2023 //
ENDPTS
Neurona Presents Data from First-Ever Regenerative Human Cell Therapy Trial
21 Nov 2022 //
GLOBENEWSWIRE
Neurona Therapeutics Presents Clinical Case Study from First Human Trial
21 Sep 2022 //
GLOBENEWSWIRE
Neurona Begins Dosing in Trial of Regenerative Human Cell Therapy, NRTX-1001
29 Jun 2022 //
GLOBENEWSWIRE
Neurona to Present PC Data Supporting Regenerative Cell Therapy, NRTX-1001
17 Jun 2022 //
GLOBENEWSWIRE
Neurona Therapeutics Awarded $8M by CIRM to Support PI/II Trial of NRTX-1001
26 May 2022 //
GLOBENEWSWIRE
Neurona Therapeutics to Present at the Locust Walk Stem Cell Tx Conference
04 Apr 2022 //
GLOBENEWSWIRE
Neurona Therapeutics Presents Preclinical Data at the AAN on NRTX-1001
01 Apr 2022 //
GLOBENEWSWIRE
Neurona to Present New Preclinical Data and Clinical Trial Plans for NRTX-1001
03 Dec 2021 //
GLOBENEWSWIRE
Neurona Therapeutics to Present at the Piper Sandler 33rd AHC
18 Nov 2021 //
GLOBENEWSWIRE
Neurona Presents Preclinical Data from Lead Cell Therapy Candidate NRTX-1001
08 Nov 2021 //
GLOBENEWSWIRE
Neurona Therapeutics Receives IND Clearance to Initiate Phase 1/2 Clinical Trial
04 Nov 2021 //
GLOBENEWSWIRE
Neurona Therapeutics Appoints Brad Margus to its Board of Directors
20 Oct 2021 //
GLOBENEWSWIRE
Neurona Therapeutics is dashing to the clinic with its cell therapy for epilepsy
23 Jun 2021 //
ENDPTS
Neurona Raises $41.5M to Advance Neural Network-Rebalancing Cell Therapies
22 Jun 2021 //
GLOBENEWSWIRE
Neurona Presents Clinical Development Plan at AEDD TRIALS XVI
16 Jun 2021 //
GLOBENEWSWIRE
